Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine TAPB + Oxycodone PCIA for Postoperative Gastrointestinal Function
NCT07651722Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial of liposomal bupivacaine and oxycodone in postoperative pain and postoperative ileus (POI) (3 arms), sponsored by Tianjin First Central Hospital. Primary endpoint: Area Under Curve of I-FEED Score at 7 days. Started Jun 2026; status: recruiting.
02
Drugs
liposomal bupivacaineoxycodone
03
Conditions
postoperative painpostoperative ileus (POI)
Beyond the preview
Go deeper on NCT07651722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07651722.